Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 400 shares, a decrease of 92.0% from the April 30th total of 5,000 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 13,300 shares, the days-to-cover ratio is presently 0.0 days.

Scinai Immunotherapeutics Stock Down 1.5%

Shares of SCNI opened at $2.69 on Friday. The business’s fifty day moving average price is $2.60 and its two-hundred day moving average price is $3.12. The firm has a market capitalization of $2.69 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. Scinai Immunotherapeutics has a 52 week low of $1.90 and a 52 week high of $8.92. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.16 and a current ratio of 1.16.

Scinai Immunotherapeutics (NASDAQ:SCNI) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($10.40) earnings per share for the quarter. The company had revenue of $0.21 million for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.